Heart & Diabetes Research Institute

Melbourne, Australia
Time filter
Source Type

PubMed | Heart & Diabetes Research Institute
Type: Journal Article | Journal: Current pharmaceutical design | Year: 2012

Type 1 diabetes mellitus (T1DM) is an autoimmune disease, due to the immune-mediated destruction of pancreatic -cells, whose incidence has been steadily increasing during the last decades. Insulin replacement therapy can treat T1DM, which, however, is still associated with substantial morbidity and mortality. For this reason, great effort is being put into developing strategies that could eventually prevent and/or cure this disease. These strategies are mainly focused on blocking the immune system from attacking -cells together with functional islet restoration either by regeneration or transplantation. Recent experimental evidences suggest that TNFrelated apoptosis-inducing ligand (TRAIL), which is an immune system modulator protein, could represent an interesting candidate for the cure for T1DM and/or its complications. Here we review the evidences on the potential role of TRAIL in the management of T1DM.

Loading Heart & Diabetes Research Institute collaborators
Loading Heart & Diabetes Research Institute collaborators